Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
Current Pediatric Research ; 26(7):1289-1298, 2022.
Article in English | EMBASE | ID: covidwho-2091678

ABSTRACT

Background: The novel Coronavirus Disease 2019 (COVID-19) is a cause of respiratory/systemic disorder which is spread in the world since September 2019 and is now a serious pandemic. To date, there is limited data on children available in the literature especially in Middle East. Objective(s): In this article, we aimed to provide an overview of clinical and laboratory data in children with COVID-19 admitted in Mashhad, Iran. Method(s): This was a cross sectional study that was related to the Registry of COVID19 Pediatric patients in Mashhad (RCPM), from 20 February 2020 to 5 August 2020 in Akbar and Dr. Sheikh Hospitals, the tertiary referral centers of pediatric COVID19 patients in Northern East of Iran. Demographic information, clinical symptoms, laboratory results, management, and outcome data from each patient's medical records were recorded. Result(s): In this period, from 1245 patients referred to our center, 97 patients were positive for COVID19 with PCR or serologic test. Majority of them were male (58, 59.8%). The median age of patients was 5.5 years old. The mean time from beginning the symptoms to hospitalization was 6.72 +/- 9.02 days. The most age groups were 1-5 years old (28.9%) Twenty patients lead to pneumonia (20.6%), eight of them lead to Multi-Inflammatory Syndrome Of Children (MISC) (8.2%), Kawasaki disease was seen in 4 patients (4.1%), myocarditis in 4 patients (4.1%) and 14 patients were died (14.4%). Conclusion(s): The existence of asymptomatic cases indicates the difficulty in identifying pediatric patients without clear epidemiological information. This finding suggests a dangerous situation if community acquired infections occur. Copyright © 2022 Scientific Publishers of India. All rights reserved.

2.
Iranian Journal of Pediatrics ; 30(2), 2020.
Article in English | GIM | ID: covidwho-1726648

ABSTRACT

The coronavirus disease 2019 (COVID-19) outbreak initiated in Wuhan, China and has spread rapidly all around the world and labeled as a pandemic with almost 168,000 infected cases and 6,500 deaths globally up to March 16, 2020. It is believed that children are less likely than adults to be infected with COVID-19. In this review, we discuss different aspects of COVID-19 infection in pediatrics. COVID-19 in pediatrics occurs in the early stages of its outbreak at a high rate with a family cluster pattern mainly. Children infected with COVID-19 are mostly asymptomatic carriers and the main potential causes of the spread and transmission of the disease in communities. Asymptomatic children with no underlying disease or red flags should follow home isolation protocols. Children with red flags, comorbidities and risk factors or those with severe pneumonia must be admitted to the hospitals. Children's hospitals should be equipped with the acute respiratory diseases ward, quarantine rooms, and intensive care unit to protect other patients and health care staff during the COVID-19 outbreak.

3.
Journal of Computational Biophysics and Chemistry ; 20(3):305-322, 2021.
Article in English | Web of Science | ID: covidwho-1582945

ABSTRACT

COVID-19 is the last disease caused by SARS-CoV-2 associated with a severe immune response and lung damage. The main protease (M-pro) has a vital role in SARS-CoV-2 proliferation. Moreover, humans lack homologous M-pro, which makes the M-pro a suitable drug target for the development of SARS-CoV-2 drugs. The purchasable L5000 library (Selleckchem Inc) includes 99,040 compounds that were used for virtual screening. After molecular docking and ADME studies, we selected a compound (WAY-604395) with a potent binding affinity to the M-pro active site and acceptable ADME properties compared to the reference drug (nelfinavir). Molecular dynamics (MD) simulation outcomes have proved that the M-pro-WAY604395 complex possesses a considerable value of flexibility, stability, compactness and binding energy. Our Molecular Mechanics Poisson-Boltzmann Surface Area (MM-PBSA) calculation demonstrates that WAY-604395 is more potent (-272.19kcal mol-1) in comparison with nelfinavir (-173.39mol-1) against SARS-CoV-2 M-pro. In conclusion, we suggest that WAY-604395 has the potential for the treatment of SARS-CoV-2 by inhibition of the M-pro. Computational modeling was performed to investigate the binding effects of WAY-604395 on SARS-CoV-2 main protease. Through molecular docking and molecular dynamics, compound WAY-604395 was selected to inhibit Mpro. ADME analysis showed that WAY-604395 is not prohibited for human use.

4.
Iranian Journal of Radiology ; 18(2), 2021.
Article in English | Scopus | ID: covidwho-1310202

ABSTRACT

Context: This review aimed to investigate the computed tomography (CT) imaging features of coronavirus disease 2019 (COVID-19). Evidence Acquisition: Bilateral lung involvement (70%), peripheral distribution (67.5%), multifocal involvement (67.3%) and ground glass opacity (66.1%) were observed in most infected patients Results: Evaluation of the number of lobes involved in infected patients showed no abnormalities in 7.2% (85/1177) of the patients. Regarding the performance of reverse transcription-polymerase chain reaction (RT-PCR) and chest CT scan, the sensitivity of RT-PCR and chest CT imaging was estimated at 70% (925/1311) and 89% (6605/7396) upon admission, respectively;nevertheless, the sensitivity of CT imaging increased as the time from the symptom onset increased. The CT image acquisition parameters affecting image quality and patient dose were also discussed. Studies suggested that these factors should be adjusted according to the disease stage. Based on our findings, sensitivity was adequately high eight days after the onset of symptoms. Conclusion: Therefore, there is no need for high-resolution chest CT scan after this interval. Using ImpactDose software, the mean effective doses were 4.38 and 5.71 mSv in male and female groups, respectively. The risk of cancer was 36% higher in females than males, as shown by PCXMC program. © 2021, Author(s).

SELECTION OF CITATIONS
SEARCH DETAIL